ClinicalTrials.gg
RecruitingNCT05976997Updated May 18, 2026

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

A Phase 2 interventional study of Duvelisib, Chidamide in Newly Diagnosed Peripheral T-cell Lymphoma, sponsored by Liling Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by Liling Zhang · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral — 17 open to participants now, 18 under way, 2 of them phase 3. tucidinostat · Lymphoma, T-Cell, Peripheral.

Planned enrollment
18th of 29
36 · median 44
Started
2023
with 4 others
Phase 2
16 of 29
8 open now
Primary completion
2026-10
later than 6 of 17 live
Registered
20th of 29
by date
Lead sponsor
1 of 29
Liling Zhang

Among the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, this one is the 18th largest by planned enrollment, is one of 5 that started in 2023, is one of 16 in phase 2, reaches primary completion later than 6 of the 17 other live ones, and was the 20th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

17 of the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral are open now, in 2 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.

Read the detailed description

This is a prospective, single arm, single center study, including two phases. It plans to recruit36 patients with clinically diagnosed primary PTCL who will be treated with Duvelisib and Chidamide. In the first phase Duvelisib is Oral administration at a dose of 25mg twice a day, and every 4 weeks (28 days) was a cycle. Next administration will be depend on whether the efficacy reaches CR in the second phase.

03

Conditions studied

  • Newly Diagnosed Peripheral T-cell Lymphoma

Keywords

  • Duvelisib
  • Chidamide
  • Peripheral T-cell Lymphoma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

1.Age: 18-70 Years (Contains boundary values 18 and 70);

  • 2.The newly diagnosed PTCL confirmed by histopathology is one of the following subtypes;

    a) Angioimmunoblastic T-cell lymphoma (AITL); b) Follicular T helper cell lymphoma (T-FHCL); Including but not limited to the above two subtypes;

  • 3. ≤ 3;
  • 4.At least one measurable or evaluable tumor lesion according to the Lugano-2014 standard;
  • 5.Expected survival ≥ 3 months;
  • 6.Subjects fully understand and voluntarily participate in this study and sign ;

Exclusion criteria

Exclusion Criteria:

-

1.Subjects who have previously received systemic treatment for lymphoma or currently undergoing anticancer treatment;

  • 2.Subjects with central nervous system (CNS) lymphoma or lymphoma involving CNS;
  • 3.Significant active heart disease within the past 6 months, including: (NYHA) Class III/IV congestive heart failure unstable angina pectoris or angina requiring surgical or medication intervention, and/or myocardial infarction;
  • 4.Uncontrolled systemic fungal, bacterial, or viral infections (defined as persistent signs/symptoms related to infection that have not improved despite the use of appropriate antibiotics, antiviral therapy, and/or other treatments);
  • 5. (HIV), or infection and history of severe skin reaction;
  • 6.Subjects with any other active malignant tumor at the time of screening, except for adequately treated cervical Carcinoma in situ or breast cancer Carcinoma in situ, skin Basal-cell carcinoma or local skin squamous cell carcinoma;
  • 7.Pregnant women, lactating women, patients who refused to take effective measures during the study;
  • 8.Any serious uncontrolled systemic disease;
  • 9.increasing the risk of the subject or interfering with the test results determined by the investigator;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Duvelisib-Chidamide

    Patients with newly diagnosed PTCL were treated with a combination of Duvelisib and Chidamide. The dose of Duvelisib was 25mg twice a day. Every 4 weeks (28 days) is a cycle with a total of 2 cycles.

    Drug: Duvelisib, Chidamide

Interventions

06

What researchers measure

Primary outcomes

  1. Safety: Hematologic and non-hematologic toxicities (NCI CTCAE v5.0)

    To identify the incidence of AE and SAE in clinical trial

    Time frame: from the initiation of the first dose to 28 days after the last dose

Secondary outcomes

  1. Objective response rate (ORR)

    To evaluate the efficacy of anti-lymphoma

    Time frame: up to 26 weeks

  2. Complete remission rate (CR)

    To evaluate the efficacy of anti-lymphoma

    Time frame: up to 26 weeks

  3. Duration of Response(DOR)

    To evaluate the efficacy of anti-lymphoma

    Time frame: The time from the first assessment as CR or PR to the first assessment as PD or death (due to any cause),assessed up to 12 months

  4. Progression free survival (PFS)

    To evaluate the efficacy of anti-lymphoma

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months

  5. Overall survival (OS)

    To evaluate the efficacy of anti-lymphoma

    Time frame: From date of randomization until the date of death from any cause, assessed up to 20 months

07

Study locations

1 of 1 sites recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Liling Zhang, M.D · Contactlily1228@sina.com · 0086 27 83262660
    • Liling Zhang, M.D · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Oct 2026, 41 months after the start.

Of 44 non-industry phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 110. This study's planned 41 months is below that.

Counting every sponsor, half of 64 studies reached it within 61 months; a quarter within 38 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2023
First posted
Aug 4, 2023
StartActual
May 8, 2023
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05976997
Lead sponsor
Liling Zhang
Responsible party
Liling Zhang (chief physician, Huazhong University of Science and Technology) — Sponsor-investigator
First posted
Aug 4, 2023
Start date
May 8, 2023
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 18, 2026

Study contacts

Liling Zhang, M.D
Contact
lily1228@sina.com
0086 27 83262660
Liling Zhang, M.D
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Duvelisib · Tucidinostat

Start the discussion